8-K: Roivant Announces Positive Trial Results and $1.5 Billion Share Repurchase Program

Roivant Sciences Ltd. announced positive Phase 2 trial results for brepocitinib in non-infectious uveitis and a $1.5 billion share repurchase program, including the repurchase of all shares held by Sumitomo Pharma.

Summary

• Roivant has announced positive results from its Phase 2 NEPTUNE study of brepocitinib for non-infectious uveitis (NIU).
• The 45mg dose of brepocitinib showed a 29% treatment failure rate at week 24, which is the best result observed in active NIU studies using this endpoint.
• The study also showed positive results across all secondary efficacy endpoints, including improvements in macular edema.
• Roivant's board has authorized a share repurchase program of up to $1.5 billion.
• This program includes the repurchase of all 71.3 million shares held by Sumitomo Pharma for approximately $648.4 million.
• The Sumitomo Pharma repurchase will reduce Roivant's outstanding shares by about 9%.

Sentiment

Score: 9

Explanation: The document is highly positive due to the strong clinical trial results and the significant share repurchase program, indicating confidence in the company's future.

Positives

• The 45mg dose of brepocitinib demonstrated a 29% treatment failure rate, which is superior to previous studies in NIU.
• The study showed positive results across all secondary efficacy endpoints, including improvements in macular edema.
• The share repurchase program of up to $1.5 billion indicates confidence in the company's financial position.
• The repurchase of Sumitomo Pharma's shares reduces shareholder concentration and increases the exposure of remaining shareholders to the company's progress.
• Brepocitinib has now shown positive results in seven Phase 2 studies with over 1,400 subjects and patients treated.

Negatives

• The 15mg dose of brepocitinib had a higher treatment failure rate of 44% compared to the 29% rate of the 45mg dose.
• The share repurchase program may be suspended or discontinued at any time, and there are no guarantees on the number of shares that will be repurchased or at what price.

Risks

• The timing and total amount of share repurchases will depend on market conditions and other investment opportunities.
• There is no guarantee that the company will repurchase all shares under the program.
• The company operates in a competitive and rapidly changing environment with new risks emerging from time to time.
• Actual results may differ materially from forward-looking statements due to various risks and uncertainties.

Future Outlook

Roivant plans to initiate a Phase 3 program for brepocitinib in NIU in the second half of 2024 and expects data from the Phase 3 dermatomyositis study in 2025. The company will continue to evaluate share repurchase opportunities based on market conditions.

Management Comments

• Matt Gline, CEO of Roivant, stated that the transaction along with further potential buybacks reduces shareholder concentration and efficiently retires shares.
• Matt Gline also stated that the transaction increases continuing shareholders exposure to developments in NIU and to the rest of our upcoming clinical data and company progress.
• Ben Zimmer, CEO of Priovant, stated that the results give them high confidence heading into Phase 3.
• Ben Zimmer also stated that the results point to a potentially highly differentiated product profile for brepocitinib in NIU.

Industry Context

The positive results for brepocitinib in NIU are significant as there is a high unmet need for effective treatments for this condition, which can lead to blindness. The share repurchase program also signals confidence in the company's future prospects and may be seen as a positive move by investors.

Comparison to Industry Standards

• The 29% treatment failure rate in the 45mg brepocitinib arm is approximately twice the observed benefit seen in the corresponding registrational study for the only approved non-steroidal therapy in NIU.
• The study was designed with a more aggressive steroid taper than precedent studies, making the results even more impressive.
• The results position brepocitinib as a potentially transformative once-daily oral therapy for NIU, an orphan indication with few other therapies approved or in development.

Related Party Transactions

• The share repurchase agreement with Sumitomo Pharma is a related party transaction.

Stakeholder Impact

• Shareholders will benefit from the share repurchase program, which reduces the number of outstanding shares and potentially increases the value of their holdings.
• Patients with NIU may benefit from the development of brepocitinib as a new treatment option.
• Employees may be positively impacted by the company's progress and financial stability.

Next Steps

• Priovant intends to initiate a Phase 3 program in NIU in the second half of 2024.
• The ongoing Phase 3 study evaluating brepocitinib in dermatomyositis is expected to be fully enrolled in the third calendar quarter of 2024.
• Data from the Phase 3 study evaluating brepocitinib in dermatomyositis is expected in calendar year 2025.
• Roivant will continue to evaluate share repurchase opportunities based on market conditions.

Key Dates

Keywords

brepocitinib, non-infectious uveitis, share repurchase, autoimmune, clinical trial, NEPTUNE study, Sumitomo Pharma, TYK2/JAK1 inhibitor, dermatomyositis, macular edema